Genetica and GenomicDAO’s core technology, upon which it conducts its testing, is built across three key pillars – gene decoding chips, artificial intelligence, and blockchain.

The growth of Precision Medicine sector

Precision Medicine is an innovative approach to disease prevention and treatment that considers people's genetic, environmental & lifestyle, of which global market size was valued at USD 66.1 billion in 2021 and is expected to reach USD 175.64 billion by 2030 (source: Precedence Research). 

The sector is poised to grow at a compound annual growth rate (CAGR) of 11.5% during the forecast period 2022 to 2030, due to the advancement in cancer biology, increased adoption of gene therapy globally, rising use of big data analytics in precision medicine in developed countries, and patient involvement in personal healthcare.

Established in 2015, at the heart of Precision Medicine’s fastest-growing market Asia Pacific, Genetica has steadily captured the movement with over 100,000 genetic profiles through its proprietary gene decoding services using artificial intelligence. 

GenomicDAO | A Decentralized Autonomous Organization 

GenomicDAO breaks free from the centralization of modern medicine R&D by establishing a community that initiates, drives, and governs precision medicine initiatives. 

Members are incentivized for contributing funds and genetic data to GenomicDAO precision medicine initiatives and reap the financial and medical benefits and successes. 

Marketplace | One-stop Shop for Genetic Products

GenomicDAO's ultimate goal is to develop working products addressing the health causes initiated by its community. Created and owned by GenomicDAO, these genetic products across the GenomicDAO evolution include genetic insights, personalized recommendations, and precision medicine drugs.

Eventually, the GenomicDAO platform will serve as the launchpad to bootstrap various precision medicine initiatives, followed by a dedicated subsidiary DAO.

To accomplish such progressive goals, GenomicDAO is built on a strong foundation consisting of proprietary technology in partnership with top gene decoding companies, led by biotech veterans, and a world-class advisory board in both the traditional and blockchain space. 

Genetica Achievement Highlights: 

• $2.5M Raised in Seed Round within 30 days
• Partnership with Illumina® & Thermo Fisher, two of the world's leading genomics organizations
• Expansive 20+ products in the portfolio from comprehensive healthcare to nutrition, sports, and early disease prevention (stroke, allergy, diabetes, cancer,...)
• Proven accuracy of 99.9% by the US technology standards
• Awarded The Best AI-Powered Genetic Testing Biotech Company by Global Health & Pharma 
• Advised by top scientists from world-renowned universities such as UCSF, Harvard, Stanford, Cornell

GenomicDAO has kicked off its first initiative - GenomicDAO G-Stroke with the official token listing set on February 20, 2023. 

PCSP: Governance & Utility token of GenomicDAO G-Stroke

Full tokenomics: https://docs.genomicdao.com/genomicdao-whitepaper/token-economy 

Details about token PCSP:

• Token Symbol: PCSP
• Network: BEP-20
• Total Supply: 1,000,000,000
• Public Sale: N/A

Token allocation: 

• Community Development: 100,000,000
• Developer Endowment: 100,000,000
• Strategic Partners: 50,000,000
• Liquidity: 50,000,000
• Team: 100,000,000
• Advisor: 50,000,000
• R&D: 150,000,000
• Reserved for GenomicDAO's next stage evolution: 100,000,000
• GenomicDAO Launchpad: 300,000,000